Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276246 | 0.83 | LRRK2 (0.40) | LRRK2PARP1PDE9ASYK | |
| SCHEMBL3276941 | 0.82 | LRRK2 (0.37) | LRRK2PARP1PDE9AKAT2BBAZ2B | |
| SCHEMBL6494796 | 0.80 | PARP1 (0.36) | PARP1IP6K1IP6K3 | |
| SCHEMBL4030932 | 0.78 | PARP1 (0.47) | LRRK2PARP1PDE9APIK3CDPIK3CA | |
| SCHEMBL3275587 | 0.76 | LRRK2 (0.41) | LRRK2PARP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3276589 | 0.75 | SRC (0.39) | LRRK2 | |
| SCHEMBL4031371 | 0.71 | PARP1 (0.45) | LRRK2PARP1SYK | |
| SCHEMBL3193077 | 0.71 | LRRK2 (0.41) | LRRK2PARP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13606773 | 0.69 | PIK3CD (0.49) | LRRK2PARP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1015994 | 0.69 | EGFR (0.48) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | LRRK2 2872/4885PARP1 281/4885PDE9A 2998/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | LRRK2 2863/4885PARP1 125/4885PDE9A 3040/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | LRRK2 2872/4885PARP1 281/4885PDE9A 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.